Tower Research Capital (TRC)’s Allarity Therapeutics ALLR Stock Holding History

Tower Research Capital (TRC)’s Portfolio ALLR Stock Details ALLR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.42K	Buy	+2,650	New	+$3.76K	﹤0.01%	4538
2025 Q3	–	Sell	-3,073	Closed	-$3.1K	–	5203
2025 Q2	$3.1K	Sell	3,073 -1,632	-35%	-$1.54K	﹤0.01%	4550
2025 Q1	$4.41K	Buy	4,705 +439	+10%	+$454	﹤0.01%	4260
2024 Q4	$4.99K	Buy	4,266 +863	+25%	+$1.14K	﹤0.01%	4365
2024 Q3	$7.18K	Buy	3,403 +2,998	+740%	+$14.1K	﹤0.01%	4070
2024 Q2	$2.59K	Buy	405 +395	+3,950%	+$15.5K	﹤0.01%	4987
2024 Q1	$1.72K	Buy	10 +1	+11%	+$251	﹤0.01%	5199
2023 Q4	$3.05K	Hold	9	–	–	﹤0.01%	5135
2023 Q3	$4.18K	Buy	9 +7	+350%	+$8.97K	﹤0.01%	4905
2023 Q2	$9.43K	Buy	+2	New	+$23.8K	﹤0.01%	4283
2023 Q1	–	Hold	0	–	–	–	5307
2022 Q4	–	Hold	0	–	–	–	5537
2022 Q1	–	Hold	0	–	–	–	6060
2021 Q4	–	Hold	0	–	–	–	6104

Other funds holding ALLR

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

MCM

Militia Capital Management Austin, Texas $3.37B AUM

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Tower Research Capital (TRC)'s ALLR Position: Q2 2026 in Review

Tower Research Capital (TRC) opened a new position in Allarity Therapeutics (ALLR) in Q2 2026: 2,650 shares worth $3.42K. The stake represents ﹤0.01% of the portfolio and ranks #4538 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in ALLR as recently as Q2 2025.

Tower Research Capital (TRC) first reported a position in ALLR in Q2 2023 and has held it in 10 quarters since. The position peaked at $9.43K in Q2 2023. 20 funds tracked by Wall St. Rank hold ALLR as of Q2 2026.

Tower Research Capital (TRC) held 2,650 shares of Allarity Therapeutics worth $3.42K as of Q2 2026.
Allarity Therapeutics was a new Tower Research Capital (TRC) position in Q2 2026.
Allarity Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4538 holding.
Tower Research Capital (TRC) first reported a position in Allarity Therapeutics in Q2 2023 and has held it in 10 quarters since.
Tower Research Capital (TRC)'s Allarity Therapeutics position peaked at $9.43K in Q2 2023.
20 funds tracked by Wall St. Rank held Allarity Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.